Drug intelligence / Profile preview

xiaozhong formula granule

Development stage: Unknown
Lead developer: Eye Hospital, China Academy of Chinese Medical Sciences
Administration: Oral

Overview

Xiaozhong formula granule is a Traditional Chinese Medicine (TCM) compound preparation developed by the Eye Hospital of the China Academy of Chinese Medical Sciences. It is designed as an oral therapeutic for diabetic macular edema (DME), a condition characterized by fluid accumulation in the macula. The formula is based on TCM principles aimed at resolving blood stasis and draining dampness to alleviate retinal swelling. In clinical settings, it is primarily investigated as an adjunctive treatment to be used alongside intravitreal anti-VEGF injections, such as conbercept, with the goal of improving visual outcomes and reducing the frequency of invasive injections.

Other names: Xiaozhong formulaXiaozhong granules消肿方

Beyond the preview

Go deeper on xiaozhong formula granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiaozhong formula granule.

Explore the full profile